Table 1 Demographic and clinical characteristics.
Characteristic | HCTZ (n = 26) | Placebo (n = 25) | p-value |
|---|---|---|---|
Age (years) | 64 ± 16 | 64 ± 10 | 0.94 |
Male gender (%) | 69 | 48 | 0.12 |
White race (%) | 92 | 76 | 0.14 |
Baseline NYHA | 2.7 ± 0.8 | 2.3 ± 0.9 | 0.11 |
Ischemic etiology (%) | 50 | 44 | 0.67 |
Hypertension (%) | 73 | 72 | 0.93 |
Diabetes mellitus (%) | 27 | 44 | 0.20 |
Ejection fraction (%) | 30 ± 8 | 31 ± 10 | 0.50 |
ICD (%) | 7.7 | 12 | 0.67 |
CRT (%) | 0 | 4 | 0.49 |
Atrial fibrillation (%) | 39 | 44 | 0.69 |
Previous stroke (%) | 15 | 20 | 0.73 |
Current/past smoking (%) | 65 | 60 | 0.69 |
Beta-blocker (%) | 85 | 80 | 0.73 |
ACEI/ARB (%) | 92 | 76 | 0.14 |
Outpatient furosemide (mg) | 58 ± 57 | 75 ± 73 | 0.50 |
Outpatient spironolactone (mg) | 8 ± 12 | 14 ± 15 | 0.15 |
Weight (kg) | 81 ± 25 | 78 ± 19 | 0.65 |
Systolic blood pressure (mm Hg) | 117 ± 17 | 122 ± 22 | 0.32 |
Diastolic blood pressure (mm Hg) | 72 ± 14 | 73 ± 13 | 0.91 |
Heart rate (bpm) | 85 ± 19 | 91 ± 21 | 0.31 |
Sodium (mEq/L) | 140 ± 4 | 139 ± 3 | 0.41 |
Potassium (mEq/L) | 4.5 ± 0.5 | 4.6 ± 0.5 | 0.43 |
Urea (mg/dL) | 50 ± 23 | 54 ± 18 | 0.55 |
Creatinine (mg/dL, mean ± SD) | 1.23 ± 0.29 | 1.24 ± 0.34 | 0.94 |
